Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity.
Reads0
Chats0
TLDR
Findings indicate that PDE4 inhibitors can affect T cell responses by acting at the DC level and may increase the understanding of the therapeutic implication of PDE 4 inhibitors for T(h)1-mediated disorders.Abstract:
Inhibitors of cAMP-specific phosphodiesterase (PDE) 4 have been shown to inhibit inflammatory mediator release and T cell proliferation, and are considered candidate therapies for T(h)1-mediated diseases. However, little is known about how PDE4 inhibitors influence dendritic cells (DC), the cells responsible for the priming of naive T(h) cells. Therefore, we investigated the PDE profile of monocyte-derived DC, and whether PDE4 inhibitors modulate DC cytokine production and T cell-polarizing capacity. We mainly found cAMP-specific PDE4 enzymatic activity in both immature and mature DC. In contrast to monocytes that mainly express PDE4B, we found that PDE4A is the predominant PDE4 subtype present in DC. Immature DC showed reduced ability to produce IL-12p70 and tumor necrosis factor (TNF)-alpha upon lipopolysaccharide or CD40 ligand (CD40L) stimulation in the presence of PDE4 inhibitors, whereas cytokine production upon CD40L stimulation of fully mature DC in the presence of PDE4 inhibitors was not affected. Exposure to PDE4 inhibitors for 2 days during DC maturation did not influence T cell-stimulatory capacity or acquisition of a mature phenotype, but increased the expression of the chemokine receptor CXCR4. Furthermore, DC matured in the presence of PDE4 inhibitors showed reduced capacity to produce IL-12p70 and TNF-alpha upon subsequent CD40L stimulation. Using these PDE4 inhibitor-matured DC to stimulate naive T cells resulted in a reduction of IFN-gamma-producing (T(h)1) cells. These findings indicate that PDE4 inhibitors can affect T cell responses by acting at the DC level and may increase our understanding of the therapeutic implication of PDE4 inhibitors for T(h)1-mediated disorders.read more
Citations
More filters
Journal ArticleDOI
Pentoxifylline: a potential therapy for chronic kidney disease.
TL;DR: Animal and cellular studies have demonstrated the rationale for pentoxifylline's efficacy in reducing proteinuria in patients with diabetes receiving angiotensin‐converting enzyme inhibitors, and in Patients with nephrotic syndrome refractory to conventional immunosuppressive therapy.
Journal ArticleDOI
Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Hunar Abdulrahim,Samuel Thistleton,Adewale Adebajo,Tim Shaw,Christopher J Edwards,Alvin F. Wells +5 more
TL;DR: The pharmacokinetic properties of apremilast and available data demonstrating significant benefits to both clinical and histological features of inflammatory arthritis are described, including short- and long-term efficacy outcomes and, importantly, the safety profile.
Journal ArticleDOI
Cyclic AMP concentrations in dendritic cells induce and regulate Th2 immunity and allergic asthma.
Jihyung Lee,Tae Hoon Kim,Fiona Murray,Xiangli Li,Sara S. Choi,David H. Broide,Maripat Corr,Jongdae Lee,Nicholas J. G. Webster,Paul A. Insel,Eyal Raz +10 more
TL;DR: It is demonstrated that low cAMP levels in DC induce Th2-biased responses in vitro and in vivo, which implies that G protein-coupled receptors, the physiological regulators of Gαs and Gαi activation and cAMP formation, act via PKA to regulate Th bias in DC and in turn, Th 2-mediated immunopathologies.
Journal ArticleDOI
Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
C. Wu,S. Rajagopalan +1 more
TL;DR: Derangement of the PDE4‐cAMP signalling represents a pathophysiologically relevant pathway in metabolic disorders as demonstrated through a critical role in the processes including inflammation, disordered glucose and lipid metabolism, hepatic steatosis, abnormal lipolysis, suppressed thermogenic function and deranged neuroendocrine functions.
Journal ArticleDOI
Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis.
TL;DR: The once-weekly treatment of atopic dermatitis and allergic contact dermatitis with cilomilast and tacrolimus with or without rapamycin is described as a new treatment option for these diseases.
References
More filters
Journal ArticleDOI
Dendritic cells and the control of immunity
TL;DR: Once a neglected cell type, dendritic cells can now be readily obtained in sufficient quantities to allow molecular and cell biological analysis and the realization that these cells are a powerful tool for manipulating the immune system is realized.
Journal ArticleDOI
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
TL;DR: Cultured DCs are as efficient as antigen-specific B cells in presenting tetanus toxoid (TT) to specific T cell clones and their efficiency of antigen presentation can be further enhanced by specific antibodies via FcR- mediated antigen uptake.
Journal ArticleDOI
Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.
TL;DR: The capacity of DCs to capture and process antigen could be modulated by exogenous stimuli was investigated and it was found that DCs respond to tumor necrosis factor alpha, CD40 ligand, IL-1, and lipopolysaccharide with a coordinate series of changes that include downregulation of macropinocytosis and Fc receptors, disappearance of the class II compartment, and upregulation of adhesion and costimulatory molecules.
Journal ArticleDOI
Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation.
TL;DR: It is found that ligation of CD40 by CD40L triggers the production of extremely high levels of bioactive IL-12, which is the most potent stimulus in upregulating the expression of ICAM-1, CD80, and CD86 molecules on DCs.
Journal ArticleDOI
Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
TL;DR: The role played by chemokines and chemokine receptors in positioning T cells for the immune response is reviewed, with a focus on T-cell priming and delayed-type hypersensitivity or allergic reactions.